SALT LAKE CITY, May 4, 2026, 08:02 MDT
- The FDA meeting minutes indicated that Clene’s CNM-Au8 data could back an accelerated-approval NDA for ALS.
- The company is eyeing a third-quarter 2026 filing, and it’s setting up a confirmatory Phase 3 trial to kick off in early 2027.
- Shares last changed hands at $6.94, up 80 cents. Earlier, the stock hit an intraday high of $9.74.
Clene Inc. is moving to pursue faster U.S. approval for its ALS drug candidate, CNM-Au8. The company cited FDA meeting minutes indicating its current data could support a New Drug Application—the key step toward seeking FDA clearance for a new therapy.
This shift is significant for the small Salt Lake City biotech, clearing up its regulatory route in ALS—a deadly nerve disease that remains short on therapies and has seen drug setbacks late in development. Clene now says it’s aiming to file in the third quarter of 2026, pushing back from its prior goal to submit by the end of June.
The question centers on neurofilament light, or NfL—a blood marker linked to nerve-cell injury and neurodegeneration. According to the FDA, NfL might qualify as a “reasonably likely surrogate endpoint,” which means it could be used as a stand-in marker, suggesting whether patients gain actual benefit. GlobeNewswire
Clene shares changed hands at $6.94, up 80 cents on the session, after hitting $9.74 earlier in Nasdaq action. About 15.1 million shares moved. Market cap hovered around $71.7 million.
The FDA wants Clene to show stronger proof that the drop in NfL measured with CNM-Au8 actually benefits ALS patients. Clene says it’s ready—those details are set to go into the application.
Clene president and CEO Rob Etherington called the upcoming NDA submission “an important milestone” for both CNM-Au8 and ALS patients. Etherington also noted the company aims to kick off a Phase 3 confirmatory trial in the first quarter of 2027. GlobeNewswire
The filing is set to rely on biomarker and clinical results pulled from the Phase 2 HEALEY ALS Platform Trial, its open-label extension, the Phase 2 RESCUE-ALS study, plus a National Institutes of Health-backed expanded-access protocol. According to Clene, the data package features NfL reductions tied to longer survival in open-label follow-up.
CNM-Au8, Clene’s gold nanocrystal oral suspension, is intended to enhance how cells use energy and shield nerve cells. The company is running additional trials of this drug platform for Parkinson’s disease and multiple sclerosis.
There’s some precedent here, though it’s limited. The FDA granted accelerated approval to Biogen and Ionis’s Qalsody for SOD1-ALS last year, using plasma NfL reduction as the basis. Mitsubishi Tanabe’s Radicava still stands as the wider ALS option on the market. Amylyx, after its Phase 3 ALS trial came up short, pulled Relyvrio from shelves in both the U.S. and Canada.
Clene still hasn’t secured approval, and the FDA wording doesn’t rule out a different decision down the line. Accelerated approval offers an earlier path to the market using a surrogate marker, yet drugmakers are still on the hook to prove clinical benefit. If those follow-up trials fall short, the FDA holds the option to pull the drug.
Funding remains a cloud over the company. As of Dec. 31, 2025, Clene held $5.2 million in cash and cash equivalents. In its 2025 annual report, the company warned it wouldn’t have sufficient cash to last the next 12 months without new financing—which throws its ability to keep operating into question.
Back in March, the company disclosed that a registered direct offering completed in January brought in an initial $6 million-plus, securing funding through the third quarter of 2026. More cash could be unlocked if certain regulatory milestones are met, potentially stretching the runway into 2027.
